Intuitive Surgical stock absorbs $450 million antitrust charge

Intuitive Surgical reported strong operating growth for the quarter ended September 30, 2026, but a proposed antitrust settlement sharply reduced reported earnings. In its third-quarter earnings release published on October 20, the company said revenue increased 22 percent from the prior-year quarter to 3.05 billion US dollars.

Revenue growth remains broad

Worldwide procedures across the da Vinci and Ion platforms rose approximately 15 percent year over year. Da Vinci procedures increased approximately 14 percent, while Ion procedures grew approximately 31 percent. Instruments and accessories revenue climbed 18 percent to 1.80 billion US dollars, supported by higher procedure volumes and a larger installed base.

Intuitive placed 546 da Vinci surgical systems, compared with 427 a year earlier. The quarter included 315 da Vinci 5 placements, up from 240 in the same period of 2025. The da Vinci installed base reached 12,094 systems at September 30, an increase of 12 percent year over year. The Ion installed base grew 21 percent to 1,152 systems.

Settlement weighs on reported profit

The company recorded a 450 million US dollar pre-tax charge tied to an agreement to settle previously disclosed antitrust class-action litigation. Intuitive said the proposed settlement includes a one-time payment and injunctive relief, without an admission of liability or wrongdoing. The agreement remains subject to preliminary and final court approval.

GAAP net income attributable to Intuitive Surgical fell to 523 million US dollars, or 1.49 US dollars per diluted share, from 704 million US dollars, or 1.95 US dollars, in the prior-year quarter. The litigation expense reduced after-tax earnings by 347 million US dollars, or 0.99 US dollars per diluted share. On a non-GAAP basis, net income increased to 1.05 billion US dollars, or 3.00 US dollars per diluted share, from 867 million US dollars, or 2.40 US dollars.

Outlook keeps investors focused

Management expects worldwide da Vinci procedure growth of 14 percent to 15 percent in 2026 and said growth should be closer to the midpoint of that range. It also forecasts non-GAAP gross margin of 68.7 percent to 69.3 percent and non-GAAP operating-expense growth of 11 percent to 13 percent for the year.

CEO Dave Rosa said customers used Intuitive systems for more than 10,000 procedures per day on average during the quarter. For investors, the central tension is between sustained procedure growth and the near-term effects of the settlement, tariffs and the company’s continuing investment in new systems.

The real-time quote of Intuitive Surgical stock traded at 384.85 euros on Lang & Schwarz at 11:24 CET on Monday, November 2, 2026.

Broader market sentiment remains relevant for large US healthcare technology stocks; see the latest S&P 500 market coverage.

More news and analyses on Intuitive Surgical stock.